Tempest Therapeutics Inc (FRA:3OS0) Stock News, Headlines & Updates
Tempest Therapeutics Inc Stock News from GuruFocus
- 1
Jun 30, 2025
Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China
Marketwired • 7:00am
Jun 11, 2025
Tempest Announces $4.6 Million Registered Direct Offering of Common Stock
Marketwired • 8:00am
Tempest Therapeutics (TPST) Announces New Stock Purchase Agreement | TPST Stock News
GuruFocus News • 7:45am
Tempest Announces $4.6 Million Registered Direct Offering of Common Stock | TPST Stock News
GuruFocus News • 7:18am
Jun 05, 2025
TPST Receives EMA Orphan Drug Designation for Liver Cancer Treatment | TPST Stock News
GuruFocus News • 7:16am
Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC
Marketwired • 7:00am
May 13, 2025
Tempest Reports First Quarter 2025 Financial Results and Provides Business Update
Marketwired • 4:00pm
TPST Highlights Promising Data for Cancer Therapy | TPST Stock News
GuruFocus News • 3:54pm
Tempest Reports First Quarter 2025 Financial Results and Provides Business Update | TPST Stock News
GuruFocus News • 3:45pm
Apr 28, 2025
Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting
Marketwired • 4:00pm
Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting | TPST Stock News
GuruFocus News • 3:19pm
Apr 21, 2025
Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP | TPST Stock News
GuruFocus News • 7:21am
Tempest Therapeutics (TPST) Gains FDA Orphan Drug Status for TPST-1495 | TPST Stock News
GuruFocus News • 7:16am
- 1
Show
Entries
Headlines
Total 0- 1
No recent news